Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

THRON-SEC: Drug-Induced Secretome Profiling for Enhanced Therapy

Project description

Secretome profiling as a marker of drug efficacy

Medications can alter the secretome by influencing the types and amounts of proteins that cells release, reflecting changes in cellular metabolism, immune response or stress. These drug-induced changes in secreted proteins can provide important insights into the drug's efficacy, toxicity or potential to induce resistance, serving as early biomarkers for treatment outcomes. The ERC-funded THRON-SEC project aims to validate the technical and commercial feasibility of secretome profiling as a tool for assessing drug efficacy and safety. The study is based on a novel technique called THRONCAT that enables the identification and quantification of secreted proteins containing chemically modified analogues of the amino acid threonine.

Objective

Under normal conditions, cells release proteins (secretome) to regulate fundamental processes like metabolism and immunity. Many diseases and their corresponding treatments involve alterations in the secretome and the cellular microenvironment. Understanding drug-induced changes in the secretome is vital for early assessment of drug efficacy, toxicity, and resistance development. We have developed a metabolic protein labeling technique based on bioorthogonal threonine analogues, THRONCAT, that offers sensitive and non-perturbing analysis of drug-induced changes in the cellular secretome. THRONCAT enables the identification and quantification of secreted proteins in response to drug treatment, even in sensitive cellular systems. We envision that Drug-Induced Secretome Profiling (DISP), holds promise for improving clinical and preclinical drug development by detecting specific signaling proteins and biomarkers early in the development process and validated secreted proteins may serve as biomarkers to assess treatment efficacy during drug development and clinical trials. In this proof of concept proposal we will validate the technical and commercial feasibility of a platform that allows the analysis of the cellular secretome upon drug treatment. THRON-SEC will: 1) Show that secretome profiling upon drug treatment allows the elucidation of a drugs efficacy and mechanism of action as well as early detection of toxicity and resistance markers; and 2) Perform IPR, market and business case analyses to ensure commercial feasibility and entry to market.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

UNIVERSITEIT LEIDEN
Net EU contribution
€ 150 000,00
Address
RAPENBURG 70
2311 EZ Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)